The new automated COVID-19 IgG assay is now available for sale!
To order our automated COVID-19 IgG assay please contact your local sales support team:
Or your local sales representative
|Germany Customer Service
Tel: +49 69 26019 0960
|France Customer Service
Tel: +33 1 40 77 04 60
|UK Customer Service
Tel: +44 (0) 191 519 6155
|TGS COVID-19 lgG||CVCL100G||100 Tests|
|TGS COVID-19 Control Set||CVCLCSGM||2 Level|
TGS COVID-19 IgG QUANTITATIVE assay
The COVID-19 IgG assay, a product of our partnership with Technogenetics, is designed to run on our IDS-iSYS Multi-Discipline Automated System, to reduce the testing time and meet demand associated with SARS-CoV-2 antibody testing, providing a fast and efficient test with a high degree of sensitivity and specificity.
Why choose our assay for SARS-CoV-2 antibodies?
Unlike many existing SARS-CoV-2 serology assays, ours is a QUANTITATIVE assay which determines antibody concentration rather than a “yes/no” result. Although the clinical level of functional immunity conferred by SARS-CoV-2 IgG antibodies has not yet been determined, we believe quantitative tests will ultimately be valuable in determining immunity status based on the levels of antibody in the blood. Our test offers a sensitivity of 100% and specificity of 99.4%.*
All steps of the COVID-19 IgG serology assay are automated with no manual reagent preparation required, ensuring minimal hands-on time for lab staff, and a high daily throughput with first results available within 25 minutes.
IDS-iSYS Multi- Discipline Automated Analyser
The IDS-iSYS is a unique compact, benchtop instrument based on Chemiluminescence and Absorbency technology. As a fully-automated solution the IDS-iSYS provides quality and efficiency throughout the complete testing process. The IDS-iSYS has on board refrigeration, ready to use reagents continuous loading, batch and STAT functionality and is easy to operate with auto start-up and shut-down functionality. For more information about our IDS-iSYS, click here
*Diagnostic sensitivity of the test was calculated across 110 samples drawn from symptomatic Italian patients in March and April 2020. For blood samples taken 21 days or more after onset of symptoms, diagnostic sensitivity was 100% (all samples positive). The diagnosis of SARS-CoV-2 infection of those patients was confirmed in nasopharyngeal swab samples by RT-PCR, specific for the SARS-CoV-19 virus
Initial data demonstrated an overall diagnostic specificity of 99.4%, with 331 of 333 presumptive negative samples testing negative with the test. These negative samples came from both pre-epidemic blood donors, as well as routine laboratory samples taken during the epidemic, some with influenza or other potentially interfering pathologies.